PDF Cover

Lisocabtagene Maraleucel Market

The market for Lisocabtagene Maraleucel was estimated at $1.6 billion in 2024; it is anticipated to increase to $4.8 billion by 2030, with projections indicating growth to around $12.0 billion by 2035.

Report ID:DS1804042
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Biotechnology
Lisocabtagene Maraleucel
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Lisocabtagene Maraleucel Market Outlook

Revenue, 2024

$1.6B

Forecast, 2034

$10.0B

CAGR, 2025 - 2034

19.9%

The Lisocabtagene Maraleucel industry revenue is expected to be around $2.0 billion in 2025 and expected to showcase growth with 19.9% CAGR between 2025 and 2034. The strong growth trajectory highlights the increasing clinical importance of advanced cell-based immunotherapies in modern oncology treatment strategies. Lisocabtagene maraleucel continues to gain relevance as healthcare providers prioritize targeted therapies capable of delivering durable responses in patients with difficult-to-treat hematologic malignancies. Growing adoption of chimeric antigen receptor T-cell therapies is supported by improving clinical outcomes, expanding treatment centers, and increasing physician familiarity with cell therapy protocols. Regulatory support for innovative oncology treatments and ongoing clinical studies exploring earlier-line treatment settings are further strengthening the therapy’s market position. In addition, pharmaceutical companies and healthcare systems are investing in specialized manufacturing and treatment infrastructure to support the delivery of personalized cell therapies. These factors collectively reinforce the strategic role of lisocabtagene maraleucel within the evolving immuno-oncology landscape.

Lisocabtagene maraleucel is an autologous chimeric antigen receptor T-cell therapy designed to target the CD19 antigen expressed on malignant B cells. The therapy is primarily used in the treatment of certain relapsed or refractory B-cell lymphomas, including large B-cell lymphoma, where conventional therapies have shown limited effectiveness. It works by collecting a patient’s T-cells, genetically modifying them to recognize cancer cells, and reinfusing them to stimulate a targeted immune response. Key advantages include its defined cell composition, which helps improve treatment consistency and manage toxicity risks. Demand for lisocabtagene maraleucel is supported by the growing prevalence of hematologic cancers, increasing acceptance of CAR-T therapies, and continued clinical research expanding potential indications. Advances in cell therapy manufacturing and improved patient management protocols are also contributing to wider adoption across specialized oncology treatment centers.

Lisocabtagene Maraleucel market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Lisocabtagene Maraleucel Market Outlook

Market Key Insights

  • The Lisocabtagene Maraleucel market is projected to grow from $1.6 billion in 2024 to $10.0 billion in 2034. This represents a CAGR of 19.9%, reflecting rising demand across Cancer Immunotherapy, CAR-T Therapy, and Personalized Medicine.

  • Bristol-Myers Squibb Company is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Lisocabtagene Maraleucel market and are expected to observe the growth CAGR of 19.1% to 27.9% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and Poland are expected to observe highest growth with CAGR ranging between 14.9% to 20.7%.

  • Slow adoption of Transition from Conventional Chemotherapy to Targeted Cell-Based Immunotherapies transition within key players in Lisocabtagene Maraleucel market is creating a revenue window for adjacent and alternate markets like Axicabtagene Ciloleucel and Tisagenlecleucel to improve its use-case penetration in Relapsed or Refractory Large B-cell Lymphoma and Diffuse Large B-cell Lymphoma applications and expected to capture $424 million revenue from existing Lisocabtagene Maraleucel market.

  • The Lisocabtagene Maraleucel market is set to add $8.4 billion between 2024 and 2034, with manufacturer targeting Diffuse Large B-cell Lymphoma & High-grade B-cell Lymphoma Application projected to gain a larger market share.

  • With Widespread prevalence of b-cell lymphoma, and advancements in CAR-T Cell Therapies, Lisocabtagene Maraleucel market to expand 514% between 2024 and 2034.

lisocabtagene maraleucel market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Lisocabtagene Maraleucel - Country Share Analysis

Opportunities in the Lisocabtagene Maraleucel

Ongoing clinical research evaluating CAR T therapies for additional hematologic malignancies is creating another important opportunity for lisocabtagene maraleucel. Researchers are investigating its potential effectiveness in treating other B cell cancers such as chronic lymphocytic leukemia and follicular lymphoma. Expanding the therapy into new indications could significantly broaden its addressable patient population. Pharmaceutical companies and academic research institutions are also forming strategic collaborations to accelerate clinical development of advanced CAR T therapies. If future trials demonstrate positive outcomes, lisocabtagene maraleucel could gain regulatory approvals for additional cancer types, strengthening long term market growth potential.

Growth Opportunities in North America and Europe

North America represents the leading regional market for lisocabtagene maraleucel, driven by strong adoption of advanced CAR-T cell therapies and well-established oncology treatment infrastructure. The United States in particular benefits from early regulatory approvals and expanded indications for Breyanzi in several B-cell malignancies, including follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma, which significantly broaden the eligible patient population. Key drivers include high healthcare spending, advanced cancer treatment centers, and strong reimbursement frameworks that support the commercialization of high-value personalized therapies. The region also benefits from rapid integration of precision oncology and cell therapy platforms within leading hospitals and academic cancer institutes. However, competition is intensifying from other CD19-directed CAR-T therapies such as axicabtagene ciloleucel and tisagenlecleucel, which compete in similar lymphoma indications. Major opportunities lie in expanding use in earlier-line treatment settings, strengthening hospital-based cell therapy networks, and increasing adoption in relapsed or refractory hematologic cancers across the United States and Canada.
Europe is emerging as a significant growth region for lisocabtagene maraleucel as healthcare systems gradually expand access to advanced cell-based immunotherapies. The European Commission approved Breyanzi for several relapsed or refractory B-cell lymphomas, enabling commercialization across EU member states and strengthening Bristol-Myers Squibb’s presence in the regional CAR-T therapy market. Growth in Europe is supported by increasing investment in specialized cell therapy centers, rising clinical trial activity, and expanding reimbursement frameworks for innovative oncology treatments. Countries such as Germany, France, Italy, and the United Kingdom are leading adoption due to their advanced oncology infrastructure and strong academic research networks. However, competition remains strong from other approved CAR-T therapies as well as emerging next-generation cell therapies under clinical development. Key opportunities include improving treatment accessibility through regional manufacturing collaborations, expanding indications in indolent lymphomas, and strengthening partnerships between pharmaceutical companies and national healthcare systems to support broader CAR-T therapy adoption.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Relapsed B-Cell Lymphomas and Advancements in CAR-T Therapy Platforms

The increasing incidence of relapsed or refractory B-cell lymphomas is also a key factor driving demand for lisocabtagene maraleucel. Many patients with aggressive large B-cell lymphoma experience relapse after standard chemotherapy or stem cell transplantation, creating a strong clinical need for advanced treatment options. Lisocabtagene maraleucel addresses this need by providing a targeted immune therapy capable of producing durable responses in difficult-to-treat cases. As diagnosis rates improve and oncology centers identify more eligible patients, the demand for CAR-T therapies continues to expand. In parallel, rapid technological progress in CAR-T therapy platforms is also strengthening the therapy’s clinical adoption. also advances in cell engineering, optimized viral vectors, and improved manufacturing protocols have also enhanced the safety, efficacy, and consistency of CAR-T treatments. Lisocabtagene maraleucel’s defined composition of CD4 and CD8 CAR-T cells also represents a significant technological improvement that supports controlled dosing and predictable clinical outcomes. These developments are also reinforcing physician confidence and expanding the use of CAR-T immunotherapies across specialized oncology treatment centers.
A major driver for the lisocabtagene maraleucel market is also the rapid expansion of global cell therapy infrastructure. Governments, pharmaceutical companies, and healthcare systems are also investing heavily in advanced manufacturing facilities, specialized treatment centers, and clinical training programs to support CAR-T therapy delivery. These investments are also enabling more hospitals to administer complex autologous cell therapies safely and efficiently. Specialized oncology centers are also also developing integrated patient management systems for cell collection, genetic modification, and reinfusion procedures. As a result, patient access to CAR-T treatments such as lisocabtagene maraleucel is also gradually expanding beyond a limited number of academic hospitals. This growing treatment network supports wider clinical adoption and strengthens the commercial outlook for advanced cell-based immunotherapies in the global oncology market.
02

Restraint: Extremely High Treatment Costs and Reimbursement Challenges Limiting Widespread Patient Access

One of the most significant restraints affecting the lisocabtagene maraleucel market is the exceptionally high cost of CAR-T therapy. The acquisition cost of a single treatment is reported to exceed $500,000 per administration, making it substantially more expensive than many conventional oncology therapies. This pricing places considerable financial pressure on healthcare systems and insurance providers, often leading to strict reimbursement conditions and limited patient eligibility. Hospitals must also absorb additional costs related to leukapheresis, lymphodepleting chemotherapy, hospitalization, and post-infusion monitoring. As a result, many healthcare providers restrict CAR-T therapy availability to select patients and specialized centers, which reduces overall treatment volumes and slows market penetration despite strong clinical efficacy.
03

Opportunity: Expanding Second Line Treatment Adoption for Relapsed Large B Cell Lymphoma Patients and Growing CAR T Therapy Infrastructure Across Asia Pacific Advanced Oncology Markets

A major opportunity for lisocabtagene maraleucel lies in its increasing adoption as a second line treatment for relapsed or refractory large B cell lymphoma. Historically, CAR T therapies were primarily used after multiple prior treatments had failed. However, recent clinical evidence supports earlier use in the treatment pathway, particularly for patients who relapse after initial chemotherapy. This shift allows oncologists to introduce cell based immunotherapy earlier, improving potential response rates and survival outcomes. As treatment guidelines gradually evolve to incorporate CAR T therapy sooner, demand for lisocabtagene maraleucel is expected to expand significantly within specialized oncology centers.
The rapid development of CAR T therapy infrastructure across Asia Pacific presents a strong growth opportunity for lisocabtagene maraleucel. Countries such as Japan, South Korea, and China are investing heavily in advanced oncology treatment capabilities and cell therapy manufacturing facilities. These investments include specialized CAR T treatment centers, clinical research collaborations, and regulatory frameworks supporting innovative cancer therapies. As healthcare systems strengthen their capabilities to manage complex cell based treatments, more hospitals are expected to become authorized providers. This expanding treatment network will increase patient access and support stronger adoption of lisocabtagene maraleucel in emerging oncology markets.
04

Challenge: Limited Treatment Infrastructure and Complex Manufacturing Process Restricting Therapy Availability

Another major restraint is the limited infrastructure required to administer CAR-T therapies such as lisocabtagene maraleucel. These therapies must be delivered in specialized oncology centers equipped with trained staff and advanced cell-processing capabilities. In many regions, only a small number of hospitals are authorized to administer CAR-T treatments, forcing patients to travel long distances or face delays in therapy access. Additionally, the manufacturing process itself is complex because it involves collecting patient T-cells, genetically modifying them, and expanding them under strict quality conditions. Manufacturing failures may occur due to insufficient cell counts or contamination, which can delay treatment and increase costs. These operational challenges restrict scalability and slow broader commercialization of lisocabtagene maraleucel within the global oncology market.

Supply Chain Landscape

1

Cell Collection

Terumo BCTFresenius KabiHaemonetics
2

Gene Engineering

Lonza GroupWuXi AppTecCatalent Inc.
3

CAR-T Manufacturing

Bristol-Myers Squibb Company
4

Clinical Treatment

Cancer ImmunotherapyCAR-T TherapyPersonalized Medicine
Lisocabtagene Maraleucel - Supply Chain

Use Cases of Lisocabtagene Maraleucel in Cancer Immunotherapy & CAR-T Therapy

Cancer Immunotherapy : Cancer immunotherapy represents a major application area for lisocabtagene maraleucel, where the therapy is used as a targeted immune-based treatment for certain B cell malignancies. Lisocabtagene maraleucel is an autologous CD19 directed CAR T cell therapy that works by modifying a patient’s own T cells to recognize and attack cancerous B cells. Oncology specialists administer this therapy primarily in advanced lymphoma cases where conventional chemotherapy or stem cell transplantation has failed. Its key advantage lies in the ability to trigger a highly specific immune response against malignant cells while limiting damage to healthy tissues. Cancer treatment centers increasingly adopt this therapy because it offers durable responses and improved clinical outcomes in relapsed or refractory hematologic cancers.
CAR-T Therapy : Lisocabtagene maraleucel is widely recognized as a specialized CAR T therapy designed to target CD19 expressing B cell cancers. In this application, patient derived T cells are collected, genetically engineered in specialized manufacturing facilities, and reinfused into the patient to activate a targeted immune attack against cancer cells. The therapy is particularly used in treating relapsed or refractory large B cell lymphoma and other aggressive lymphoid malignancies. A distinctive advantage of lisocabtagene maraleucel is its defined composition of CD4 and CD8 CAR T cells, which supports consistent dosing and improved safety management. Advanced oncology hospitals and cell therapy treatment centers rely on this therapy due to its potential to produce long lasting remission in patients with limited treatment options.
Personalized Medicine : Personalized medicine represents another important application of lisocabtagene maraleucel, as the therapy is developed using an individual patient’s own immune cells. This autologous approach allows clinicians to design a highly tailored treatment that aligns with the patient’s specific disease characteristics. Hospitals specializing in advanced oncology care use lisocabtagene maraleucel to provide individualized immunotherapy solutions for patients with aggressive B cell lymphomas. The therapy offers advantages such as targeted tumor recognition, improved immune activation, and the potential for durable treatment responses. Growing emphasis on precision oncology and individualized treatment strategies is encouraging healthcare systems to expand CAR T therapy programs, which is expected to strengthen demand for personalized cell based cancer therapies like lisocabtagene maraleucel.

Impact of Industry Transitions on the Lisocabtagene Maraleucel Market

As a core segment of the Biotechnology industry, the Lisocabtagene Maraleucel market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Conventional Chemotherapy to Targeted Cell-Based Immunotherapies and Expansion of Personalized Medicine and Advanced Cell Therapy Manufacturing Ecosystems have redefined priorities across the Biotechnology sector, influencing how the Lisocabtagene Maraleucel market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Conventional Chemotherapy to Targeted Cell-Based Immunotherapies

The oncology industry is gradually transitioning from conventional chemotherapy and monoclonal antibody regimens toward advanced CAR-T cell therapies such as lisocabtagene maraleucel. This shift reflects increasing demand for targeted treatments capable of delivering durable responses in patients with relapsed or refractory B-cell lymphomas. Hospitals and cancer centers are investing in specialized cell therapy infrastructure to support such treatments, influencing growth across the biopharmaceutical manufacturing and clinical services sectors. For example, the rising adoption of CAR-T therapies is driving expansion in viral vector production, cryogenic logistics, and cell processing technologies. As precision oncology continues to evolve, therapies like lisocabtagene maraleucel are reshaping treatment protocols and encouraging pharmaceutical companies to prioritize cell-based therapeutic development.
02

Expansion of Personalized Medicine and Advanced Cell Therapy Manufacturing Ecosystems

Another key transition is the expansion of personalized medicine, where patient-specific therapies such as lisocabtagene maraleucel are becoming central to modern cancer treatment strategies. Unlike traditional drugs produced in large batches, CAR-T therapies require individualized manufacturing using a patient’s own T cells. This transformation is reshaping supply chains across the biotechnology industry, driving demand for advanced cell processing platforms, bioprocessing equipment, and specialized contract manufacturing services. Companies involved in cell therapy logistics, cryopreservation, and gene modification technologies are experiencing increased collaboration with pharmaceutical developers. As healthcare systems adopt more personalized oncology approaches, the ecosystem supporting cell therapy manufacturing, regulatory frameworks, and hospital-based treatment centers is expanding significantly, reinforcing the commercial potential of therapies like lisocabtagene maraleucel.